



MPS PHARMAA LIMITED
(FORMERLY ADVIK LABORATORIES LIMITED)

Dated: 28.05.2025

**The Manager (Listing),
Bombay Stock Exchange Limited,
1st Floor, P. J. Towers,
Dalal Street,
Mumbai - 400001**

**Subject: Disclosure of related party transaction for the half year ended March 31, 2025
pursuant to Regulation 23(9) of the SEBI (LODR), Regulation, 2015**

Ref: BSE Scrip Code- 531686; ASE Scrip Code-01636 (ADVIKLABO)

Dear Sir,

As per the requirements of Regulation 23(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed herewith disclosure under "Related Party Transaction" for the half year ended 31st March, 2025 , in the required format.

We hope that you will find the above in order.

This is for your information and records please.

Thanking You.

**Yours Faithfully,
For MPS Pharmaa Limited
(Formerly Advik Laboratories Limited)**

**POOJA
CHUNI**

Digitally signed by
POOJA CHUNI
Date: 2025.05.28
18:13:49 +05'30'

**Pooja Chuni
Company Secretary**

Encl: As Above

CC:

**The Manager (Listing)
Ahmedabad Stock Exchange Ltd.,
1st Floor, Kamdhenu Complex,
Opp. Sahajanand College, Panjarapole,
Ambawadi, Ahmedabad - 380015**

CIN No. : L74899HR1994PLC038300

Corporate Office : 703, Arunachal building 19, Barakhamba Road, Connaught Place, New Delhi 110001

Phones: 011-42424884, 43571040-45, Fax: 011-43571047

**Regd. Office & Factory: 138. ROZ-KaMeoIndustrial Area,Sohna - 122103 (Distt.Mewat), Haryana
Phones: 0124-2362471 Email:mail@advikindia.comWebsite: www.advikindia.com**

Amount Rs. In Lacs											Additional disclosure of related party transactions - applicable only in case the related party transactions are loans, inter-corporate deposits, advances or investments							
S. No	Details of the party (listed entity)		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due		In case any financial			Investments			Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)	
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost (see Note 7)	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure		Secured/ unsecured
1	MPS Pharmaa Limited (Formerly Advik Laboratories Ltd)	AAACA8545R	Mr. Peeyush Kumar Aggarwal	AACPA6470C	Member of Promoter Group & Managing Director	Unsecured Loans received	50.00	2.3	38.91	41.21								
2	MPS Pharmaa Limited (Formerly Advik Laboratories Ltd)	AAACA8545R	Omkam Global Capital Private Limited	AAACO1459Q	Common Director	Unsecured Loan received	500.00	0.00	663.78	663.78								
3	MPS Pharmaa Limited (Formerly Advik Laboratories Ltd)	AAACA8545R	Mr. Manoj Bhatia	AAZPB5897R	Chief Financial Officer	Remuneration Paid	15.00	2.31	1.16	1.54								
4	MPS Pharmaa Limited (Formerly Advik Laboratories Ltd)	AAACA8545R	Mr. Manoj Bhatia	AAZPB5897R	Chief Financial Officer	Advance against salary	15.00	0.00	0.60	0.60			Advance	Against salary		unsecured	Personal use for medical emergency*	
5	MPS Pharmaa Limited (Formerly Advik Laboratories Ltd)	AAACA8545R	Ms. Pooja Chuni	AKRPB3032A	Company Secretary	Remuneration Paid	15.00	2.00	1.20	1.60								

Notes:

1. The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party.
2. Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.
3. Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks.
4. For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31. Companies with financial years ending in other months, the six months period shall apply accordingly.

** The advance salary of Rs. 60,000/- given to Mr Manoj Bhatia, Chief Financial Officer of the company is in accordance with the conditions of service applicable to employees and is also in accordance with the remuneration policy of the company.

For MPS Pharmaa Limited
(Formerly Advik Laboratories Ltd.)

(Manoj Bhatia)
CFO

